ASX News

Telix Pharmaceuticals Limited Acquires TheraPharm GmbH

Melbourne (Australia) and Baar (Switzerland) –  30th November 2020. Telix announces it has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH, a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.

Telix Pharmaceuticals is pleased to announce it has entered into an agreement with Scintec Diagnostics GmbH (‘Scintec’) to acquire TheraPharm GmbH(‘TheraPharm’), a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology. The acquisition of TheraPharm provides Telix with access to a portfolio of patents, technologies, production systems, clinical data and know-how in relation to the use of Molecularly Targeted Radiation (MTR) in hematology and immunology.

TheraPharm is developing antibody MTR technology against CD66, a cell surface target highly expressed by neutrophils (a type of granulocyte, a category of white blood cell) and tumor-infiltrating lymphocytes. As such, the technology has potentially very broad applications in the diagnosis and treatment of hematologic diseases (e.g. blood cancers), infection management and a variety of lymphoproliferative diseases. Of particular interest is the demonstrated use of the technology to safely and effectively condition patients prior to bone marrow stem cell transplant.

 

Summary of benefits to Telix from the acquisition of TheraPharm:

  1. diagnostic imaging product (99mTc-besilesomab, marketed as Scintimun®) targeting white blood cells, for the purpose of locating areas of inflammation or infection in patients with suspected bone infection (osteomyelitis). Scintimun® is an approved product in Europe, currently sold and marketed by Curium Pharma in certain countries.
  2. Scintimun® has significant potential for expanded clinical indications for serious diseases that represent an unmet medical need.
  3. therapeutic product (90Y-besilesomab, referred to as 90Y-anti-CD66-MTR) for the purpose of bone marrow conditioning (BMC) in patients prior to undergoing hematopoietic stem cell transplant (HSCT) for the treatment of blood cancers (hematologic malignancies) and various related conditions. 90Y-anti-CD66-MTR is supported by highly promising clinical safety and efficacy data from phase I and II clinical trials, and has been granted orphan drug designation (ODD) status in Europe for the broad indication of BMC for HSCT.
  4. 90Y-anti-CD66-MTR has significant potential for fast track development for the treatment of systemic amyloid light-chain amyloidosis (SALA), a rare disease with a poor prognosis and an estimated prevalence of 30,000 and 45,000 patients in US and EU, respectively. Telix estimates the addressable market value for the SALA indication at ~USD $600M for US/EU5.
  5. Beyond SALA, 90Y-anti-CD66-MTR has therapeutic potential across a very broad range of stem cell transplant settings including for multiple myeloma and leukemia, for which there is already compelling preliminary evidence of clinical utility.
  6. Manufacture of the therapeutic product, which contains the radioisotope yttrium-90 (90Y) is uniquely suited to Telix’s Seneffe (Belgium) manufacturing facility. 90Y has already been added to the Seneffe production license in anticipation of this transaction.

To read the full media release please click here.

More Articles

ASX News

Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent

Melbourne (Australia) and Brussels (Belgium) – 19 April 2021. Telix announces the launch of the international NOBLE Registry of Telix’s...

ASX News

Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021

Melbourne (Australia) – 12 April 2021. Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12...

ASX News

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 31st March 2021. Telix announces it has completed an agreement with Grand River...

Corporate Spotlight

Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

29th March 2021 – Corporate Spotlight | Darren Patti joins Telix as Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

ASX News

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial supply...

Corporate Spotlight

Telix Appoints Sébastien Linard as General Manager, Telix European Manufacturing Facility

8th March 2021 – Corporate Spotlight | Sébastien Linard joins Telix as General Manager of Telix’s European Manufacturing in Seneffe,...

ASX News

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial...

ASX News

Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report

Melbourne (Australia) – 26th February 2021. Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.

ASX News

Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan

Melbourne (Australia) and Kyoto (Japan) – 22nd February 2021. Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a...

ASX News

Telix FY2020 Results and Company Update Conference Call

Melbourne (Australia) – 16th February 2021. Telix to present the Company’s FY2020 results together with an update on Telix’s operations.

ASX News

Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product

Melbourne (Australia) and Liège (Belgium) – 16th February 2021. Telix announces the Ministry of Health of the Czech Republic is...

ASX News

Telix and Heidelberg University Hospital to Develop Next Generation Theranostics

Melbourne (Australia) and Heidelberg (Germany) – 10th February 2021. Telix announces research cooperation agreement with Heidelberg University Hospital to develop...

Corporate Spotlight

Industry Leaders’ Round-Table at SNMMI Mid-Winter Satellite Symposium

3rd February 2021 | Corporate Spotlight – Recording of Industry Leaders’ Round-Table Discussion at SNMMI Mid-Winter Symposium: Ga-68 PSMA-11: Advances...

ASX News

First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...

Corporate Spotlight

Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific

22nd January 2021 – Corporate Spotlight | Telix Pharmaceuticals welcomes Dr Danielle Meyrick as Chief Medical Officer, Asia Pacific

Corporate Spotlight

ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target

Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...

ASX News

Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...

ASX News

Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance

Melbourne (Australia) – 16th December 2020. [Article updated with new video 16th February 2021] Telix Pharmaceuticals announces collaboration with Mauna...

ASX News

Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging

Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...

ASX News

Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data

Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...

ASX News

Telix Granted TGA Priority Review for Prostate Cancer Imaging

Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...

ASX News

Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging

Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...

ASX News

Australian TGA Accepts Telix’s Prostate Cancer Imaging Product Submission and Commences Priority Evaluation Process

Melbourne (Australia) – 14 April 2021. Telix announces the Australian Therapeutic Goods Administration has accepted its prostate cancer imaging product submission and commenced...